Biogen takes second royalties victory in blow for Forward Pharma

Danish biotech company Forward Pharma has once again lost out to US-based firm Biogen, after the European Patent Office decided to uphold the ruling that royalties are not owed.  

The European Patent Office, Munich. | Photo: Frank Leonhardt/AP/Ritzau Scanpix

US-based Biogen can celebrate another victory in its drawn-out legal battle against Forward Pharma.

Forward Pharma announced in a press release that the board of appeals at the European Patent Office has rejected the company's attempt to overturn the annulment of its European patent, EP2801355.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs